Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2025)

SAB Biotherapeutics (SABS) has disclosed Receivables - Accured for 2 consecutive years, with $946781.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Accured rose 846.78% year-over-year to $946781.0, compared with a TTM value of $946781.0 through Dec 2025, up 846.78%, and an annual FY2025 reading of $946781.0, up 846.78% over the prior year.
  • Receivables - Accured was $946781.0 for Q4 2025 at SAB Biotherapeutics, up from $560000.0 in the prior quarter.
  • Across five years, Receivables - Accured topped out at $946781.0 in Q4 2025 and bottomed at $21386.0 in Q1 2025.